Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer

Razavi, Pedram; Lee, Eunjung; Bernstein, Leslie; Berg, David Van Den; Horn‐Ross, Pamela L.; Ursin, Giske

doi:10.1002/ijc.26163

Cited by 6 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, in summary, 31 citations reporting on the incidence and prevalence of EC among women using MHT were included in this review . Among them, we found 15 cohort studies [8][9][10][11][12]14,16,17,21,[23][24][25]27,30,32], 10 case-control studies [7,[18][19][20]26,29,[33][34][35][36], 2 randomized controlled trials [6,28], 2 narrative reviews [15,31], 1 meta-analysis [22], and 1 systematic review [13], describing a total of 21,306 patients with EC.…”

Section: Resultsmentioning

confidence: 99%

“…Thus, in summary, 31 citations reporting on the incidence and prevalence of EC among women using MHT were included in this review [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. Among them, we found 15 cohort studies [ 8 , 9 , 10 , 11 , 12 , 14 , 16 , 17 , 21 , 23 , 24 , 25 , 27 , 30 , 32 ], 10 case–control studies [ 7 , 18 , 19 , 20 , 26 , 29 , 33 , 34 , 35 , 3...…”

Section: Resultsmentioning

confidence: 99%

“…An additional genetic variant modulating the risk of EC among MHT users has been described by Razawi et al [18]. They found that a variation in the CYP11A1 gene may modify the risk of postmenopausal EC conferred by estrogen-only MHT.…”

Section: Genetic Modulation Of the Association Between Mht And Ecmentioning

confidence: 89%

See 2 more Smart Citations

Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review

Tempfer

Hilal

Kern

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Menopausal hormone therapy (MHT) is an appropriate treatment for women with the climacteric syndrome. The estrogen component of MHT effectively alleviates climacteric symptoms but also stimulates the endometrium and thus may increase the risk of endometrial cancer (EC). Materials and Methods: We performed a systematic literature search of the databases PubMed and Cochrane Central Register of Controlled Trials to identify controlled and uncontrolled clinical trials reporting on the prevalence and/or incidence of EC among women using MHT. Results: 31 publications reporting on 21,306 women with EC diagnosed during or after MHT were identified. A significantly reduced risk of EC among continuous-combined (cc)MHT users with synthetic progestins (SPs) was demonstrated in 10/19 studies with odds ratios (ORs)/hazard ratios (HRs) between 0.24 and 0.71. Only one study documented an increased risk of EC among long-term users (≥10 years), not confirmed in three other sub-group analyses of women with ≥6, ≥5, and >10 years of ccMHT use. A significantly increased risk of EC among users of sequential-combined (sc)MHT with SPs was demonstrated in 6/12 studies with ORs/HRs between 1.38 and 4.35. Number of days of progestin per month was a significant modulator of EC risk. A decreased risk of EC was seen in obese women. Two studies documented an increased risk of EC among users of cc/scMHT with micronized progesterone. A significantly increased risk of EC among estrogen-only MHT users was demonstrated in 9/12 studies with ORs/HRs between 1.45 and 4.46. The adverse effect of estrogen-only MHT was greatest among obese women. Conclusion: ccMHT with SPs reduces the risk of EC, whereas estrogen-only MHT increases the risk. scMHT with SPs and cc/scMHT with micronized progesterone increase the risk of EC depending on type of progestin, progestin dosage, and duration of MHT use.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review

Tempfer

Hilal

Kern

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Furthermore, the CYP17A1 polymorphism may partly contribute to the increase in natural testosterone/epitestosterone levels since the CYP17A1 mutant A2 allele was found to be associated with increased urinary excretion of upper testosterone glucuronic acid and its presumed precursor (Schulze et al, 2008). Rs743572 is the most studied polymorphism in CYP17A1 (Razavi et al, 2012). Except for rs743572, other SNPs of CYP17A1 are rarely reported in PCOS (see Results).…”

Section: Introductionmentioning

confidence: 94%

The single-nucleotide polymorphism rs743572 of CYP17A1 shows significant association with polycystic ovary syndrome: a meta-analysis

Xu¹,

Shi

et al. 2021

Reproductive BioMedicine Online

View full text Add to dashboard Cite

Research questions: Polycystic ovary syndrome is acknowledged as the typical multifactorial reproductive and endocrine disease and believed to be produced by aberrant steroid biosynthesis pathways where Cytochrome P450, 17α-hydroxylase (CYP17A1) involves in. Consequently, this meta-analysis aimed to evaluate the association between CYP17A1 polymorphism rs743572 and PCOS risk.Design: Literature data on the CYP17A1 gene was retrieved by searching PubMed, the Embase, and the Web of Science. Statistical analyses were performed by STATA software (Version 14.0).

show abstract

“…One of the most studied polymorphisms in CYP17A1 is rs743572 [10]. Other SNPs of CYP17A1 are rarely reported in PCOS in comparison with rs743572 This SNP causes a substitution in the 5′ untranslated region from T to C [12], resulting in the variant genotypes "CC" and "CT." This SNP may improve androgen synthesis [14] and is involved in the control process of gene expression [13,14].…”

Section: Introductionmentioning

confidence: 99%

The CYP17A1 single-nucleotide polymorphism rs743572 in Iraqi polycystic ovary syndrome patients

Albedairy,

Aljawad,

AL-Shammari

et al. 2024

Preprint

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) has been found to be one of the most prevalent endocrine disorders among women of reproductive age. Genetic factors play a crucial role in the pathogenesis of PCOS. CYP17A1 gene coded for (steroid-17-α hydroxylase/17, 20 lyase) is responsible for androgenesis. This study was aimed to investigate the relationship of CYP17A1 polymorphism with polycystic ovarian syndrome susceptibility from Iraqi women. A case-control association study involving 83 healthy participants and 80 PCOS patients was carried out. Using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, the restriction endonuclease MSpAI was used to genotype the SNP rs743572 (T/C) polymorphism on genomic DNA. The statistical analysis was conducted to identify the CYP17A1 polymorphism in PCOS. The most frequent genotypes in patients and control were (T/T) and (T/C) respectively, while (T) the most frequent allele in both patients and control. The inheritance of this SNP in PCOS was under codominant, additive and dominant models. Ultimately, it has been demonstrated that the C allele provided protection. The ‘TT’ genotype was associated with PCOS patients. Further studies need to include more samples to find out the effect of this SNP on PCOS patients.

show abstract

Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer

Cited by 6 publications

References 43 publications

Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review

Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review

The single-nucleotide polymorphism rs743572 of CYP17A1 shows significant association with polycystic ovary syndrome: a meta-analysis

The CYP17A1 single-nucleotide polymorphism rs743572 in Iraqi polycystic ovary syndrome patients

Contact Info

Product

Resources

About